The FDA has granted fast track designation to an mRNA vaccine candidate from Sanofi for the prevention of chlamydia infection. The designation is aimed to address the unmet public health need caused by the bacterial infection.
According to the CDC, chlamydia is a common sexually transmitted infection (STI) caused by the bacterium Chlamydia trachomatis
that can trigger infection among men and women who are sexually active.
Although chlamydia usually does not present symptoms, it can cause severe health issues even without symptoms. This includes permanent damage to a woman’s reproductive system and potentially fatal ectopic pregnancy. Asymptomatic individuals are often left untreated, which could lead to unintentional transmission.
